DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Actimmune (Interferon Gamma-1B) - Drug Interactions, Contraindications, Overdosage, etc

 
 



DRUG INTERACTIONS

Interactions between ACTIMMUNE and other drugs have not been fully evaluated. Caution should be exercised when administering ACTIMMUNE in combination with other potentially myelosuppressive agents (see WARNINGS).

Preclinical studies in rodents using species-specific interferon-gamma have demonstrated a decrease in hepatic microsomal cytochrome P-450 concentrations. This could potentially lead to a depression of the hepatic metabolism of certain drugs that utilize this degradative pathway.

CONTRAINDICATIONS

ACTIMMUNE is contraindicated in patients who develop or have known hypersensitivity to interferon-gamma, E. coli derived products, or any component of the product.

REFERENCES

  1. Maluish AE, Urba WJ, Longo DL, et al: The determination of an immunologically active dose of interferon gamma in patients with melanoma. J Clin Onc 6: 434-445, 1988.
  2. Nathan CF, Kaplan G, Levis W, et al: Local and systemic effects of intradermal recombinant interferon gamma in patients with lepromatous leprosy. NEJM 315: 6-11, 1986.
  3. Fauci AS, Rosenberg SA, Sherwin SA, et al: Immunomodulators in clinical medicine. Ann Internal Med 106: 421-433, 1987.
  4. Snapper CM, Paul WE: Interferon-gamma and B cell stimulatory factor-1 reciprocally regulate Ig isotype production. Science 236: 944-947, 1987.
  5. King CL, Gallin JI, Malech HL, et al: Regulation of immunoglobulin production in hyperimmunoglobulin E recurrent-infection syndrome by interferon gamma. PNAS USA 86:10085-10089, 1989.
  6. Rosenbloom J, Feldman G, Freundlich B, Jimenez SA: Inhibition of excessive scleroderma fibroblast collagen production by recombinant gamma-interferon. Arth Rheum 29: 851-856, 1986.
  7. Ezekowitz RAB, Dinauer MC, Jaffe HS, et al: Partial correction of the phagocyte defect in patients with X-linked chronic granulomatous disease by subcutaneous interferon gamma. NEJM 319: 146-151, 1988.
  8. Sechler JMG, Malech HL, White CJ, Gallin JI: Recombinant human interferon-gamma reconstitutes defective phagocyte function in patients with chronic granulomatous disease of childhood. PNAS USA 85:4874-4878, 1988.
  9. Shapiro F: Osteopetrosis, current clinical considerations. Clin Orth & Rel Res 296: 34-44, 1993.
  10. Beard CJ, Key L, Newburger PE, Ezekowitz RAB, et al: Neutrophil defect associated with malignant infantile osteopetrosis. J Lab Clin Med 108: 498-505, 1986.
  11. Shankar L, Gerritsen EJA, and Key LL: Osteopetrosis: pathogenesis and rationale for the use of interferon-(gamma)-1b. Biodrugs 1: 23-29, 1997.
  12. Key LL, Rodriguiz RM, Willi SM: Long-term treatment of osteopetrosis with recombinant human interferon gamma. NEJM 24: 1594-1599, 1995.

Manufactured by:

InterMune, Inc.

Brisbane, CA 94005

U.S. License No. 1626

Revised March 2004 (A102)

© -2004 InterMune, Inc.

PH01017.00

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2012